The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time.
In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss recommendations on whether or not to wait for an NGS panel result for a newly diagnosed patient with a 90% PDL1 expression.
A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech